- Home
- SUPN vs APLS Comparison
SUPN vs APLS Comparison
Compare SUPN & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- APLS
- Stock Information
- Founded
- SUPN 2005
- APLS 2009
- Country
- SUPN United States
- APLS United States
- Employees
- SUPN N/A
- APLS N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- SUPN Health Care
- APLS Health Care
- Exchange
- SUPN Nasdaq
- APLS Nasdaq
- Market Cap
- SUPN 1.9B
- APLS 2.2B
- IPO Year
- SUPN 2012
- APLS 2017
- Fundamental
- Price
- SUPN $32.28
- APLS $17.69
- Analyst Decision
- SUPN Hold
- APLS Buy
- Analyst Count
- SUPN 2
- APLS 19
- Target Price
- SUPN $36.00
- APLS $37.67
- AVG Volume (30 Days)
- SUPN 529.3K
- APLS 2.1M
- Earning Date
- SUPN 08-05-2025
- APLS 07-31-2025
- Dividend Yield
- SUPN N/A
- APLS N/A
- EPS Growth
- SUPN N/A
- APLS N/A
- EPS
- SUPN 1.11
- APLS N/A
- Revenue
- SUPN $667,997,000.00
- APLS $775,839,000.00
- Revenue This Year
- SUPN N/A
- APLS $1.01
- Revenue Next Year
- SUPN $12.02
- APLS $22.14
- P/E Ratio
- SUPN $29.32
- APLS N/A
- Revenue Growth
- SUPN 11.82
- APLS 48.04
- 52 Week Low
- SUPN $25.55
- APLS $16.10
- 52 Week High
- SUPN $40.28
- APLS $42.47
- Technical
- Relative Strength Index (RSI)
- SUPN 48.28
- APLS 42.98
- Support Level
- SUPN $31.56
- APLS $18.26
- Resistance Level
- SUPN $33.15
- APLS $19.96
- Average True Range (ATR)
- SUPN 0.92
- APLS 0.84
- MACD
- SUPN -0.03
- APLS -0.08
- Stochastic Oscillator
- SUPN 40.34
- APLS 19.22
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.